Biogen Showcases Alzheimer’s Pipeline at AAIC 2026 with Tau and Lecanemab Data
Event summary
- Biogen will present Phase 2 CELIA data for diranersen, a tau-targeting ASO, at AAIC 2026.
- Lecanemab data will highlight subcutaneous administration and real-world use findings.
- Diranersen is being evaluated in early Alzheimer’s disease with Fast Track designation from the FDA.
- AAIC 2026 takes place July 12-15 in London, UK.
The big picture
Biogen’s AAIC 2026 presentations underscore its dual focus on tau and amyloid pathways in Alzheimer’s treatment. The company is positioning itself as a leader in both novel mechanisms (tau-targeting with diranersen) and practical delivery innovations (subcutaneous lecanemab). Success here could solidify Biogen’s role in the evolving Alzheimer’s therapeutic landscape, particularly as competitors race to address unmet needs in early-stage disease.
What we're watching
- Tau Targeting Potential
- How diranersen’s Phase 2 results will position Biogen in the tau-targeting space.
- Lecanemab Expansion
- Whether subcutaneous lecanemab can drive broader adoption and real-world efficacy.
- Regulatory Momentum
- The pace at which diranersen advances toward Phase 3 development.
Related topics